* RAPT Therapeutics Inc reported a quarterly adjusted loss of 47 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -82 cents. The mean expectation of ten analysts for the quarter was for a loss of 56 cents per share. Wall Street expected results to range from -64 cents to -37 cents per share.

* Reported revenue was zero​; analysts expected zero.

* RAPT Therapeutics Inc's reported EPS for the quarter was a loss of 47 cents​.

* The company reported a quarterly loss of $18.43 million.

* RAPT Therapeutics Inc shares had fallen by 12.9% this quarter and lost 93.0% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 2.5% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 8 "hold" and 1 "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for RAPT Therapeutics Inc is $3.00 This summary was machine generated from LSEG data November 12 at 03:26 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.56 -0.47 Beat

Jun. 30 2024 -0.72 -0.71 Beat

Mar. 31 2024 -0.81 -0.79 Beat

Dec. 31 2023 -0.86 -0.80 Beat